Phase 3 clinical trial data readouts for tarcocimab in wet AMD, DME, and RVO - particularly non-inferiority endpoints versus aflibercept and durability metrics (weeks between injections)
FDA regulatory interactions including Biologics License Application (BLA) submission timing, acceptance, and approval decisions
Partnership announcements for ex-US commercialization rights or specific indication licensing deals
Competitive landscape developments including Regeneron's Eylea HD approval/uptake, Roche's faricimab market penetration, and biosimilar threats to legacy anti-VEGF products
low - Retinal disease treatments address progressive vision loss and are medically necessary rather than discretionary. Demand is driven by aging demographics (wet AMD prevalence increases with age) and diabetes prevalence (driving DME) rather than economic cycles. However, reimbursement pressure from government and private payers can intensify during recessions, potentially affecting pricing power post-launch.
Rising interest rates negatively impact Kodiak through multiple channels: (1) Higher discount rates compress NPV of future cash flows for pre-revenue biotechs with long development timelines, (2) Increased cost of capital makes equity/debt financing more expensive and dilutive, (3) Risk-off sentiment during rate hiking cycles reduces speculative capital flows to clinical-stage biotechs, (4) Opportunity cost - investors rotate from high-risk growth stocks to safer fixed income as yields rise. The company's negative cash flow and need for external financing amplify rate sensitivity.
Binary clinical and regulatory risk - Phase 3 trial failure or FDA rejection would eliminate primary asset value and potentially trigger going concern issues given cash burn rate
Reimbursement pressure from Medicare/Medicaid and private insurers seeking to control specialty pharmaceutical costs, particularly for products without clear superiority to existing therapies
Patent cliff risk - ABC Platform patents and tarcocimab composition of matter patents have finite lives, and biosimilar competition could emerge post-exclusivity
growth/speculative - Attracts biotech-focused growth investors and hedge funds willing to accept binary risk for asymmetric upside potential. The 342.9% one-year return and 115.8% six-month return indicate momentum-driven trading and event-driven positioning around clinical catalysts. Not suitable for income or conservative value investors given zero revenue, negative cash flow, and high volatility. Institutional ownership likely concentrated among specialized healthcare funds with expertise evaluating clinical trial risk/reward.
Trend
+47.3% vs SMA 50 · +233.5% vs SMA 200
Momentum
Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $602252 $238762–$860817 | — | -$4.27 | — | ±10% | High5 |
FY2026(current) | $11.3M $4.5M–$16.2M | ▲ +1779.6% | -$3.74 | — | ±13% | High5 |
FY2027 | $45.9M $888987–$77.5M | ▲ +305.6% | -$3.12 | — | ±13% | Moderate4 |
INSTITUTIONAL OWNERSHIP
KOD News
About
Kodiak Sciences Inc. is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, Kodiak is focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Its ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, its bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and the company is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
KOD◀ | $37.02 | -4.34% | $2.0B | — | — | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.16% | — | 50.3 | +398824.8% | -4085.6% | 1500 |